Cellectis entered into a lease agreement in March of 2019 to build the Innovative Manufacturing Plant for Allogeneic Cellular Therapies (IMPACT) in Raleigh, N.C. Designed by Laporte Euro, the facility will produce immunotherapies based on gene-edited allogeneic CAR T-cells (UCART). Colliers International assisted in the real estate transaction. In addition, Cellectis is building a 14,000-sf manufacturing facility in Paris. The SMART (Starting Material Realization for CAR-T products) center will create the critical materials needed for UCART production. These two projects will enable GMP manufacturing for both clinical supplies and commercial products that meet the guidelines of the Food and Drug Administration and the European Medicines Agency.
